Month: January 2020

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will… …read more […]

While not a mind-blowing move, it is good to see that the Livent Corporation (NYSE:LTHM) share price has gained 23% in… …read more […]

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios… …read more […]

Hope Bancorp, Inc. (NASDAQ:HOPE), operating in the financial services industry based in United States, received a lot… …read more […]

When At Home Group Inc.’s (NYSE:HOME) announced its latest earnings (26 October 2019), I wanted to understand how… …read more […]

Today we’ll evaluate Herbalife Nutrition Ltd. (NYSE:HLF) to determine whether it could have potential as an investment… …read more […]

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of… …read more […]

Berkshire Hathaway is on its fourth year without making a major acquisition. …read more […]

Bob Iger became the CEO of The Walt Disney Company (NYSE:DIS) in 2005. This analysis aims first to contrast CEO… …read more […]

Drugmakers including Bristol-Myers Squibb Co, Gilead Sciences Inc, and Biogen Inc hiked U.S. list prices on more than 50 drugs on Wednesday, bringing total New Year’s Day drug price increases to more than 250, according to data analyzed by healthcare research firm 3 Axis Advisors. Reuters reported on Tuesday that drugmakers including Pfizer Inc, GlaxoSmithKline PLC and Sanofi SA were planning to increase prices on more than 200 drugs in the United States on Jan. 1. …read more […]

Drugmakers including Bristol-Myers Squibb Co, Gilead Sciences Inc, and Biogen Inc hiked U.S. list prices on more than 50 drugs on Wednesday, bringing total New Year’s Day drug price increases to more than 250, according to data analyzed by healthcare research firm 3 Axis Advisors. Reuters reported on Tuesday that drugmakers including Pfizer Inc, GlaxoSmithKline PLC and Sanofi SA were planning to increase prices on more than 200 drugs in the United States on Jan. 1. …read more […]

How far off is Groupon, Inc. (NASDAQ:GRPN) from its intrinsic value? Using the most recent financial data, we’ll take… …read more […]

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like… …read more […]